Skip to content

Illexcor

Oral drug for sickle cell disease

Raised to date

$13M

of $69M offered across 1 Form D filing

Still open
$56M
Investors
6
Last filed
May 8, 2026

About

Illexcor Therapeutics is a preclinical biopharmaceutical company developing small molecule allosteric modifiers of hemoglobin. Its lead drug ILX-002 is an oral hemoglobin S polymerization inhibitor intended to treat sickle cell disease at its root cause. The company is also evaluating compounds for other hematologic, respiratory and inflammatory disorders.

ILX-002 binds directly to hemoglobin S to block polymerization and sickling, aiming for a once-daily oral therapy with disease-modifying benefit.

Funding

  • EquityFiled May 8, 2026Form D
    $13M/ $69M

Product

ILX-002

Small molecule therapeutic

An oral small molecule that binds hemoglobin S and directly inhibits its polymerization in sickle cell disease. It is in preclinical development.

  • Direct hemoglobin S polymerization inhibitor
  • Oral, once-daily dosing goal
  • Preclinical stage, clinical trials planned

Built for

Sickle cell disease patients and the hematology clinicians who treat them

People on file